42 related articles for article (PubMed ID: 23565533)
1. Therapeutic Guide for mTOuRing through the Braided Kidney Cancer Genomic River.
Voss MH; Hsieh JJ
Clin Cancer Res; 2016 May; 22(10):2320-2. PubMed ID: 26920890
[TBL] [Abstract][Full Text] [Related]
2. Prognostic and predictive markers in metastatic renal cell carcinoma.
Khattak MA; Bakr F; Krzystanek M; Szallasi Z; Gerlinger M; Santos C; Swanton C; Pickering LM; Gore ME; Larkin JM
J Clin Oncol; 2013 Mar; 31(7):971-2. PubMed ID: 23295806
[No Abstract] [Full Text] [Related]
3. Serum lactate dehydrogenase predicts for overall survival benefit in patients with metastatic renal cell carcinoma treated with inhibition of mammalian target of rapamycin.
Armstrong AJ; George DJ; Halabi S
J Clin Oncol; 2012 Sep; 30(27):3402-7. PubMed ID: 22891270
[TBL] [Abstract][Full Text] [Related]
4. Re: Camillo Porta, Emiliano Calvo, Miguel A. Climent, et al. Efficacy and safety of everolimus in elderly patients with metastatic renal cell carcinoma: an exploratory analysis of the outcomes of elderly patients in the RECORD-1 Trial. Eur Urol 2012;61:826-33.
Procopio G; Verzoni E; De Braud F
Eur Urol; 2012 Jul; 62(1):e5-6; author reply e7-8. PubMed ID: 22487015
[No Abstract] [Full Text] [Related]
5. Pneumocystis jirovecii pneumonia in everolimus-treated renal cell carcinoma.
Loron MC; Grange S; Guerrot D; Di Fiore F; Freguin C; Hanoy M; Le Roy F; Poussard G; Etienne I; Legallicier B; Pfister C; Godin M; Bertrand D
J Clin Oncol; 2015 Mar; 33(8):e45-7. PubMed ID: 24638002
[No Abstract] [Full Text] [Related]
6. Reply to M A Khattak et al.
Armstrong AJ; George DJ; Halabi S
J Clin Oncol; 2013 Mar; 31(7):972-3. PubMed ID: 23565533
[No Abstract] [Full Text] [Related]
7. [Role of mTOR inhibition in the treatment of metastatic renal cell carcinoma].
Mizuno R; Miyajima A; Oya M
Nihon Jinzo Gakkai Shi; 2012; 54(5):581-5. PubMed ID: 22991836
[No Abstract] [Full Text] [Related]
8. Everolimus: a new mammalian target of rapamycin inhibitor for the treatment of advanced renal cell carcinoma.
Grgic T; Mis L; Hammond JM
Ann Pharmacother; 2011 Jan; 45(1):78-83. PubMed ID: 21177421
[TBL] [Abstract][Full Text] [Related]
9. mTOR-inhibition in metastatic renal cell carcinoma. Focus on temsirolimus: a review.
Gerullis H; Ecke TH; Eimer C; Heuck CJ; Otto T
Minerva Urol Nefrol; 2010 Dec; 62(4):411-23. PubMed ID: 20944541
[TBL] [Abstract][Full Text] [Related]
10. Everolimus in renal cell carcinoma.
Wang Y
Drugs Today (Barc); 2010 Aug; 46(8):557-66. PubMed ID: 20830316
[TBL] [Abstract][Full Text] [Related]
11. Everolimus for the treatment of advanced renal cell carcinoma.
Amato R
Expert Opin Pharmacother; 2011 May; 12(7):1143-55. PubMed ID: 21470068
[TBL] [Abstract][Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]